Skip to main content
7869 results
Phase 3 baricitinib trials (2890 pts) there were 215 prior/occult HBV infection (HbcAb+) and 8 (3.7%) had a positive HBV DNA+ (≥29 IU/mL). Four met the definition of reactivation and 3 required antiviral therapy = check HBV serologies with JAK inhib use https://t.co/9xGIu5hzNh

Dr. John Cush @RheumNow  (  View Tweet)

May 28, 2020
TNR Grand Rounds on "Cytokine Storm Syndromes" features a lecture and Q&A with Dr. Randy Cron - watch it here>> https://t.co/1CZ1YOY5W3 or listen on iTunes>> https://t.co/FHJv01AAbC or SoundCloud Podcast>> https://t.co/G0EuWMGTdW https://t.co/z57pBUhAKn
Dr. John Cush @RheumNow  (  View Tweet)
May 28, 2020
UPI quotes Dr. Tony Fauci stating (about hydroxychloroquine) "The scientific data is really quite evident now about the lack of efficacy". Yesterday France and other countries have banned the use of HCQ to treat COVID. https://t.co/G0EuWMGTdW

Dr. John Cush @RheumNow  (  View Tweet)

May 28, 2020
Great NY Times article on 30+ years of an adversarial friendship between Dr. Tony Fauci and AIDS activist Larry Kramer (who recently passed away). Keen that adversaries can still be on the same side, pushing for change differently https://t.co/lnfk6fXfF2

Dr. John Cush @RheumNow  (  View Tweet)

May 28, 2020
kneepain3.jpg

Targeting the Wnt Pathway Fails in OA

May 28, 2020

The Wnt pathway modulator lorecivivint failed to meet the primary endpoint in a phase IIa study for knee osteoarthritis (OA), but showed promise in certain patient subgroups, researchers reported.

Read Article
BTK inhib (fenbrutinib-FEN) effective in #RA. In a 12 wk RCT, 480 MTX-IR pts Rx either PBO, adalimumab or FEN (50 mg or 150 mg/d). ACR50 resp was PBO 15%; ADA 36%; FEN 50mg 18%, 150 qd 28%, 200 mg bid 35%. FEM NO effx on myeloid & B cell biomarkers. https://t.co/JIb4FtiOQG

Dr. John Cush @RheumNow  (  View Tweet)

May 28, 2020
NEJM reports no difference between 5d and 10d course of Remdesivir in severe Covid-19 not requiring mechanical ventilation; but this trial did not include a placebo control https://t.co/mxAR2qQzPa

Dr. John Cush @RheumNow  (  View Tweet)

May 28, 2020
CORRONA registry compared Triple DMARD (MSH) to TNF/MTX Rx; MSH is infrequently used; Triple DMARD pts were older, longer Dz duration, less Dz activity, more CA & comorbidities. Comparatively MSH had more Discontinuations & less likely to get to LDAS https://t.co/WSHgzrfcIn

Dr. John Cush @RheumNow  (  View Tweet)

May 27, 2020
artworks-r4szOJTQx34Ebvpr-ClkfXw-t500x500.jpg

TNR Grand Rounds Cytokine Storm Syndrome

May 27, 2020

Grand Rounds presentation by Dr. Randy Cron (UAB)

×